The Crosstalk Mechanism of EGFR and ER in EGFR-Mutant Lung Adenocarcinoma
The U.S. Food and Drug Administration (FDA) approved taletrectinib for adults with locally advanced or metastatic ROS1-positive (+) non-small cell lung cancer (NSCLC).
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT